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Abstract Although the majority of HIV-infected patients
who begin potent antiretroviral therapy should expect long-
term virologic suppression, the realities in practice are less
certain. Durability of viral suppression was examined to
define the best timing of targeted adherence strategies and
intensive viral load monitoring in an urban clinic popula-
tion with multiple challenges to ART adherence. We
examined the risk of viral rebound for patients who
achieved two consecutive viral loads lower than the lower
limit of quantification (LLOQ) within 390 days. For 791
patients with two viral loads below the LLOQ, viral
rebound [LLOQ from the first viral load was 36.9 %
(95 % CI 32.2–41.6) in the first year, 26.9 % (95 % CI
21.7–32.1) in the year following one year of viral sup-
pression, and 24.6 % (95 % CI 18.4–30.9) in the year
following 2 years of viral suppression. However, for
patients with CD4 C300 cells/ll who had 3–6 years of
virologic suppression, the risk of viral rebound was very
low. At the population level, the risk of viral rebound in a
complex urban clinic population is surprisingly high even
out to 3 years. Intensified monitoring and adherence efforts
should target this high risk period. Thereafter, confidence
in truly durable virologic suppression is improved.
Keywords HIV  Virologic suppression  Viral rebound 
Durability of virologic suppression  Adherence
Introduction
HIV-1 RNA viral load (VL) monitoring is currently rec-
ommended every 3–4 months for patients on antiretroviral
therapy (ART). Among those patients with suppressed viral
load for greater than 2 years, monitoring at 6 months
intervals is considered reasonable [1]. As these guidelines
are based predominantly on clinical trials and on expert
opinion, our objective was to examine the risk of viral
rebound over time in a large urban HIV Clinic, and better
define the durability of virologic suppression and its
implications for viral load monitoring and for targeted
adherence strategies.
Methods
The objective of the analysis was to describe the risk of
rebound among patients with virologic suppression. We
used the HIV Clinical Case Registry to describe the pop-
ulation of patients with HIV infection who had at least one
outpatient visit to the Washington DC Veterans Affairs
Medical Center from January 1, 2005 to December 31,
2011. We evaluated every paired HIV-1 viral load (VL)
and CD4 count performed by the Infectious Diseases
Laboratory during the period of observation. Time to
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rebound was computed using consecutive sequences of
observations for subjects whose initial two viral loads were
below the lower limit of quantification (LLOQ) and had a
viral load measurement within 390 days. Although the
median frequency of viral load monitoring for the clinic
between 1999 and 2011 was 113 days (IQR; 96–138), we
aimed to be inclusive of those patients with more minimal
monitoring up to a maximum of approximately 13 months
between measurements.
Two analyses were performed. In Analysis A, viral
rebound was defined as a viral load greater than the LLOQ. In
Analysis B, viral rebound was defined as a viral load greater
than 200 copies/ml. Subjects were classified as censored either
if they reached the end of the study while remaining virally
suppressed, or if at some point a gap of 390 days between tests
occurred. Only the first period of virologic suppression for
each patient was included in these analyses.
Kaplan–Meier and life table curves were generated to
describe time to viral rebound in the cohort. Analyses were
done on the cohort as a whole and also as stratified by CD4
groups \300 cells/ll and [300 cells/ll at the time of
inclusion. Homogeneity of survival curves in the latter case
was tested via the log rank test. Cox’s Proportional Hazards
model was also used to quantify the degree and direction of
relative risk between CD4 groups. The proportional haz-
ards assumption was assessed visually using log–log sur-
vival plots. Analysis was performed using the lifetest,
phreg, and freq procedures (SAS 9.3, Cary, NC), and data
management was performed using R 3.0.1.
Results
From January 2005 to December 2011, 1544 patients had
at least one outpatient visit. Among these patients, 97 %
were male, 75 % were black or African American, and
the median age was 50 years. Reported risks for expo-
sure to HIV included sex with a male (30 %), sex with a
female (50 %) and injection drug use (20 %). Approxi-
mately 30 % of patients were co-infected with Hepatitis
C and other co-morbid illness was common including
drug and alcohol dependence and mental health disorders
in approximately 50 % of patients. Approximately 75 %
of patients received antiretroviral therapy (ART) during
this period. Among those on ART, 30 % received a non-
nucleoside reverse transcriptase inhibitor (NNRTI) based
regimen (95 % efavirenz-based), 30 % received a pro-
tease inhibitor based regimen (85 % boosted with ri-
tonavir and 15 % unboosted), and 3 % received an
integrase inhibitor or other regimen. The remaining 37 %
of patients either switched drug classes during this per-
iod or received a regimen consisting of three or more
drug classes, predominantly nucleosides, NNRTIs and
boosted PIs.
During 2005–2011, there were a total of 14,434 paired
VL and CD4 results from 1355 patients. Of these, 791
subjects met the criteria of two consecutive viral loads
below the LLOQ within 390 days, then followed by at least
one subsequent viral load.
Overall Risk of Viral Rebound
Analysis A: Viral Rebound Defined as [LLOQ
Among our cohort of 791 patients, 431 (55 %) experienced
viral rebound. Of the 360 patients with sustained viral sup-
pression, 317 (40 % of our cohort) were censored having
reached the end of the study period without experiencing
rebound, and 43 (5 % of the cohort) were censored due to
having had a gap of at least 390 days between testing.
Analysis B: Viral Rebound Defined as [200 Viral Copies/
ml
334 patients experienced rebound with detectable viremia
[200 copies/ml. Of the remaining 457 patients with viral
suppression, 404 were censored having reached the end of
the study period without rebound and 53 for having had a
testing gap of 390 day or more (Table 1).
Risk of Rebound by CD4 Strata
As shown in Fig. 1, in an unadjusted Cox Proportional Haz-
ards model, the hazard ratio for rebound comparing patients
with CD4 C300 cells/ll to those with CD4 \ 300 cells/ll was
0.571 (95 % CI 0.470–0.693) for Analysis A, [LLOQ and
0.54 (95 % CI 0.44, 0.68) for Analysis B,[200. The log-rank
statistic which formally tests whether the Survival Curves for
each group overlap was highly significant (v2 = 32.26 for
[LLOQ and 29.99 for[200, p \ 0.0001).
Risk of Viral Rebound by Year for Analysis A,[LLOQ
As shown in Table 2 and Fig. 2, the risk of early virologic
failure[LLOQ was high. For patients with two viral loads
below the LLOQ, virologic rebound from the first viral
load was 36.9 % (95 % CI 32.2–41.6) in the first year,
26.9 % (95 % CI 21.7–32.1) in the year following one year
of viral suppression, and 24.6 % (95 % CI 18.4–30.9) in
the year following two years of viral suppression. When
stratified by CD4 cell count, patients with [300 cells/ll
were at lower risk of viral rebound than those with \300
cells/ll: 29.8 % (95 % CI 28.3–35.2) versus 54.1 % (95 %
CI 48.8–65.4) in the first year, 24.2 % (95 % CI 22.9–30.7)
versus 35.0 % (95 % CI 31.0–49.2) in the second year and
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22.9 % (95 % CI 21.3–30.8) versus 31.1 % (95 % CI
26.7–50.4) in the third year. This difference achieved sta-
tistical significance in the first year and in the second year
at p \ 0.05.
After three years of virologic suppression, the risk of
viral rebound dropped significantly. For patients who
achieved three to five years of virologic suppression, the
risk of failure were 12.8 % (95 % CI 7.3–18.2) overall and
9.7 % for CD4 [300 in the year following three years of
virologic suppression, 11.3 % overall and 7.7 % for CD4
[300 in the year following four years of virologic sup-
pression, 7.8 % overall and 6.5 % for CD4 [300 in the
year following five years of virologic suppression. For 79
patients in both CD4 strata who achieved 5.7 years of
virologic suppression, none had viral rebound at a median
of 10 months of follow-up.
Risk of Viral Rebound by Year for Analysis B, [200
The risk of viral rebound by year, defined as [200 viral
copies/ml (Table 3 and Fig. 2), in the first three years was
high. When stratified by CD4 cell count, patients with
[300 cells/ll were at lower risk of viral rebound than
those with \300 cells/ll only in the first year following
Table 1 Summary of censoring and events by CD4 strata and rebound definition
Analysis A, rebound defined [LLOQ n Sustained viral suppression Viral rebound [LLOQ Censored by testing gap [390 days
\300 cells/ll 248 73 (29 %) 163 (66 %) 12 (5 %)
[300 cells/ll 543 244 (45 %) 268 (49 %) 31 (6 %)
Total 791 317 (40 %) 431 (55 %) 43 (5 %)
Analysis B, rebound Defined [ 200 n Sustained viral suppression Viral Rebound [200 Censored by testing gap [390 days
\300 cells/ll 248 101 (41 %) 133 (54 %) 14 (6 %)
[300 cells/ll 543 303 (56 %) 201 (37 %) 39 (7 %)
Total 791 404 (51 %) 334 (42 %) 53 (7 %)
LLOQ lower limit of quantification
Fig. 1 Top panels Probability of viral rebound above lower limit of
quantification (LLOQ) where the right panels is the cohort as a whole
and the left panels is stratified by CD4 groups. Bottom panels
Probability of viral rebound above 200 where the right panels is the
cohort as a whole and the left panels is stratified by CD4 groups
596 AIDS Behav (2015) 19:594–600
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virologic suppression. Thereafter, differences by CD4
strata did not achieve statistical significance. The risk of
viral rebound dropped significantly in the year following
three years of virologic suppression and thereafter. For 119
patients in both CD4 strata who achieved 5.7 years of
virologic suppression, none had viral rebound at a median
of 10 months of follow-up.
Comparison of Viral Rebound Defined as [LLOQ
to Viral Rebound Defined as [200 copies/ml
For both CD4 strata, the yearly risk of rebound in years one
to three was approximately 10 % higher for the more
stringent definition of [LLOQ. However, following three
years of virologic suppression for the CD4[300 strata, the
Table 2 Probability of HIV rebound above the lower limit of quantitation during continuous suppression
Initial CD4 count Years of HIV
suppression (year)
No. at start
of Year
No. of
rebounds
Yearly %Probability
(95 % CI)
Cumulative % Probability
(95 % CI)
\300 cells/ll 0–1 248 99 54.1 (48.8–65.4) 43.6 (37.2–50.1)
1–2 118 32 35.0 (31.0–49.2) 59.9 (53.1–66.4)
2–3 65 16 31.1 (26.7–50.4) 70.9 (63.8–77.2)
3–4 38 8 25.8 (21.6–51.3) 77.8 (70.5–83.7)
4–5 24 6 30.8 (24.1–67.8) 83.5 (76.2–88.9)
5–6 15 2 16.0 (12.8–63.7) 86.0 (78.5–91.1)
6–7 10 0 0.0 86.0 (78.5–91.1)
[300 cells/ll 0–1 543 131 29.8 (28.3–35.2) 25.9 (22.2–29.8)
1–2 337 68 24.2 (22.9–30.7) 41.9 (37.4–46.5)
2–3 224 43 22.9 (21.3–30.8) 54.1 (49.2–58.9)
3–4 152 13 9.7 (9.2–16.8) 58.4 (53.4–63.2)
4–5 115 8 7.7 (7.3–15.3) 61.3 (56.2–66.2)
5–6 94 5 6.5 (6.1–15.5) 63.7 (58.5–6.86)
6–7 61 0 0.0 63.7 (58.5–68.6)
All combined 0–1 791 230 36.9 (32.5–41.9) 31.4 (28.1–34.8)
1–2 455 100 26.9 (22.1–32.6) 47.5 (43.7–51.3)
2–3 289 59 24.6 (19.1–31.7) 59.3 (55.2–63.2)
3–4 190 21 12.8 (8.3–19.6) 64.2 (60.1–68.1)
4–5 139 14 11.3 (6.7–19.0) 68.0 (63.8–71.9)
5–6 109 7 7.8 (3.7–16.4) 70.3 (66.0–74.2)
6–7 71 0 0.0 70.3 (66.0–74.2)
Estimates of yearly probability for HIV rebound determined by computing Hazard Rate via the Life Table method and cumulative probability by
Kaplan–Meier (SAS 9.3, Cary, NC). Analysis restricted to the first sequence of each patient with consecutive viral loads less than the lower limit
of quantitation. Sequences were right-censored 43 times because the testing interval exceeded 390 days and 317 times when the observation
period ended 31 December 2011
Fig. 2 Yearly probability of
viral rebound (left) HIV [lower
limit of quantification (LLOQ)
and (right) HIV [200. Dashed
line square CD4 \300, Solid
line circle CD4 C300
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yearly risk of rebound was equivalent regardless of defi-
nition of viral rebound.
Discussion
The primary risk of inadequate viral load monitoring is
undetected viral rebound with potential immunologic
decline, immune activation and progressive selection of
resistance mutations that limit antiretroviral options.
Although we are informed by data from clinical trials, we
conducted this study to better understand the risk of viral
rebound relative to time with virologic suppression in a
complex outpatient clinic environment. Our findings have
relevance for HIV clinic practices and further inform rec-
ommendations for the appropriate frequency of viral load
monitoring and further consideration in appropriate timing
for intensive adherence strategies.
Our prior examinations of CD4 cell count and viral loads
from 1999 to 2011 demonstrated considerable improvement
in median CD4 cell count and the percentage of patients with
virologic suppression [2] as also demonstrated elsewhere [3].
Now, in the era of potent antiretroviral therapy and capacity
for genotypic resistance testing to guide therapy, the occur-
rence of viral rebound may reflect our challenges with reten-
tion in care and adherence to antiretrovirals [4]. It is therefore
particularly disappointing that the risk of viral rebound is high
out to three years. The clinic from which this data is derived
provides both HIV care and primary care, has a ‘‘medical
home’’ approach with a nurse practitioner– physician team for
each patient, social workers and a clinical pharmacist on site
as well as availability of an HIV psychologist. Though
this model improves outcomes in the engagement in care
continuum [5, 6], we, like others have demonstrated this high
early risk for viral rebound, [4, 7–11] indicating that further
refinement of approach is warranted. These findings support
not only the suggested higher frequency of early viral load
monitoring, but also highlights the period of time when
additional strategies are needed to keep patients in care and on
treatment.
When stratified by CD4 cell count, patients with CD4
\300 had a nearly double risk of viral rebound. Higher rates
of viral rebound among patients with a low CD4 cell count
in the first three years following virologic suppression is not
Table 3 Probability of HIV rebound above 200 copies/ml during continuous suppression
Initial CD4 count Years of HIV
suppression (year)
No. at start
of year
No. of
rebounds
Yearly % probability
(95 % CI)
Cumulative % probability
(95 % CI)
\300 cells/ll 0–1 248 79 40.8 (32.9–50.7) 34.6 (28.7–41.0)
1–2 139 28 25.0 (17.3–36.1) 48.5 (41.8–55.2)
2–3 85 16 23.2 (14.3–37.7) 59.3 (52.0–62.0)
3–4 53 4 8.8 (3.3–23.4) 62.9 (55.3–69.8)
4–5 38 3 9.2 (3.0–28.6) 66.1 (58.2–73.2)
5–6 27 3 13.3 (4.3–41.2) 70.2 (61.7–77.5)
6–7 18 0 0.0 70.2 (61.7–77.5)
[300 cells/ll 0–1 543 92 20.0 (19.2–24.5) 18.2 (15.0–21.8)
1–2 377 54 16.8 (16.1–21.9) 30.8 (26.7–35.2)
2–3 266 30 12.8 (12.2–18.3) 39.2 (34.6–43.9)
3–4 202 11 6.1 (5.9–11.0) 42.8 (38.0–47.7)
4–5 159 7 4.8 (4.7–10.1) 45.4 (40.4–50.4)
5–6 131 7 6.3 (6.0–13.3) 48.6 (43.4–53.9)
6–7 90 0 0.0 48.6 (43.4–53.9)
All combined 0–1 791 171 26.2 (22.5–30.4) 23.3 (20.4–26.5)
1–2 516 82 18.9 (15.2–23.5) 36.3 (32.8–40.0)
2–3 351 46 15.2 (11.4–20.3) 45.4 (41.4–49.4)
3–4 255 15 6.6 (4.0–11.0) 48.9 (44.8–53.0)
4–5 197 10 5.6 (3.0–10.5) 51.6 (47.4–55.8)
5–6 158 10 7.5 (4.0–14.0) 55.0 (50.6–59.3)
6–7 108 0 0.0 55.0 (50.6–59.3)
Estimates of yearly probability for HIV rebound determined by computing Hazard Rate via the Life Table method and cumulative probability by
Kaplan–Meier analysis (SAS 9.3, Cary, NC). Analysis restricted to the first sequence of each patient with consecutive viral loads less than the
lower limit of quantitation. Sequences were right-censored 53 times because the testing interval exceeded 390 days and 404 times when the
observation period ended 31 December 2011
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unexpected. Patients with a low CD4 cell count (\300 cells/
ll) may represent a population who may have late HIV
diagnosis, with very low nadir CD4 and immune restoration
failure due to inability to reconstitute depleted T cell pop-
ulations despite virologic suppression. Some also have a low
CD4 due to a co-morbidity such as Hepatitis C and cirrhosis
despite virologic suppression. However, those with a CD4
cell count \300 are over-represented by those who are
under-treated for HIV due to the failure to engage in care
and attend visits to the clinic (even with two viral load
measurements in 390 days, engagement in care cannot be
assumed); and those who come to their visits but fail to take
prescribed antiretroviral therapy.
On the other hand, after 3 years of sustained virologic
suppression, the risk of rebound is quite low and our
confidence in a twice yearly monitoring strategy improves.
This risk declines even further by 6 years, an observation
also seen by Lima et al. [4]. In our analysis, viral rebound
was not seen after 5.7 years of virologic suppression
among 119 patients at risk for a median of 10 months. For
those patients with demonstrated consistent adherence and
engagement in care for five to 6 years, even further
reduction in monitoring may be rational [12].
We examined the risk of viral rebound with rebound
defined both as[LLOQ and[200 copies/ml. Although the
[200 definition is intended to allow for clinically insig-
nificant ‘‘viral blips’’ and follows the antiretroviral guide-
line definition [1], recent literature suggests an increased
risk of early viral rebound even with very low replication
of HIV [13, 14]. A more stringent definition of viral
rebound was therefore also examined. Although we did not
compare the risk of viral rebound at ‘‘not detected’’ com-
pared to \LLOQ, our data demonstrated that once viral
suppression was achieved for five to 6 years, annual failure
risk was similar regardless of rebound definition and CD4
stratification. Benzie and Lima have demonstrated dura-
bility regardless of adherence or previous treatment failures
once around 6 years of suppression are achieved [14–16],
thus true durability at the HIV population level may be best
defined after five to six years of virologic suppression.
For the individual patient, clinician decisions as to fre-
quency of viral load monitoring should be informed by
psychosocial and neurobehavioral factors [1, 17] and self-
reported adherence, pharmacy refill data or adherence
monitoring [18–20]. But the findings of this analysis
remind us to have caution; we should not assume durable
virologic suppression after one year or even two years of
virologic suppression, but carefully assess the likelihood of
viral rebound. Yet, six or more years of undetectable viral
loads for the ‘‘right’’ patient might even allow an annual
viral load monitoring strategy.
Viral load monitoring is costly and particularly prohibi-
tive in resource-limited countries. We previously
demonstrated that frequent CD4 monitoring among patients
with CD4 C300 cells/ll and virologic suppression was not
necessary [21]. A less intensive strategy for viral load
monitoring after truly durable virologic suppression has
further significant economic implications in both resource
rich and resource poor nations and warrants further pro-
spective evaluation.
Our study had several limitations. This was a retro-
spective evaluation from a single, urban medical center
caring for predominantly African-American men. The risk
of viral rebound by antiretroviral regimen was not exam-
ined. This analysis intended to address risk for the popu-
lation overall, for all patients who achieved initial virologic
suppression. We examined data beginning in 2005 when
efavirenz and simpler once daily regimens were more
widely in use to reflect the ‘‘current’’ era of ART. Although
the higher barrier to mutation of the newer once daily in-
tegrase strand transfer inhibitors may reduce the risk of
viral mutations associated with nonadherence compared to
once daily NNRTI regimens, the findings here still provide
relevant guidance to a rational approach to viral load
monitoring and to timing of strategies to improve adher-
ence and reduce the risk of viral rebound.
Conclusions
In conclusion, HIV-infected patients in our urban clinic had
high rates of viral rebound in the first three years following
virologic suppression, highlighting the time when targeted
efforts to assure antiretroviral adherence may be particularly
meaningful. On the other hand, this data demonstrated that
once virologic suppression is achieved and sustained for three
years, the risk for rebound declines substantially, supporting
guidance for reduced monitoring particularly for patients with
CD4 cell counts[300 cells/lL. As we enter eighteen years
post approval of potent antiretroviral regimens, better defining
the relative risks for viral rebound allows better and more
focused use of resources and improvement of our capacity to
achieve truly durable virologic suppression in all patients
initiating antiretroviral therapy.
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